Spots Global Cancer Trial Database for second line therapy
Every month we try and update this database with for second line therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma | NCT01470131 | Multiple Myelom... | Masitinib Placebo Bortezomib Dexamethasone | 18 Years - | AB Science | |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | NCT03760822 | Stomach Cancer Stomach Neoplas... Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | 70 Years - | Federation Francophone de Cancerologie Digestive | |
| Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | NCT01774578 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel HyperAcute®-Lun... Gemcitabine Pemetrexed | 18 Years - | Lumos Pharma | |
| BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy | NCT01806649 | Esophageal Canc... | BKM120 | - | Prince of Songkla University | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy | NCT01806649 | Esophageal Canc... | BKM120 | - | Prince of Songkla University | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | NCT03760822 | Stomach Cancer Stomach Neoplas... Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | 70 Years - | Federation Francophone de Cancerologie Digestive | |
| Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | NCT01116271 | Colorectal Canc... | AZD6244 Irinotecan | 18 Years - | AstraZeneca | |
| CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas | NCT03387592 | Neuroendocrine ... | CPT-11 Calcio levofoli... 5-Fluorouracil Capecitabine Temozolomide | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | NCT03760822 | Stomach Cancer Stomach Neoplas... Gastric Cancer Gastroesophagea... | Ramucirumab Paclitaxel | 70 Years - | Federation Francophone de Cancerologie Digestive | |
| A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer | NCT00498407 | Advanced Colore... Colorectal Canc... | CP-4055 | 18 Years - | Clavis Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma | |
| Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | NCT02460367 | Non-small Cell ... Progression of ... Non-small Cell ... | Docetaxel Tergenpumatucel... Indoximod | 18 Years - | Lumos Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
